article thumbnail

New quality requirements for tobacco products

European Pharmaceutical Review

He is currently a CMC consultant with an interest in impurities and safety‑based limits. Assessment report Procedure under Article 5(3) of Regulation EC (No) 726/2004 Nitrosamine impurities in human medicinal products Procedure number: EMEA/H/A-5(3)/1490 EMA/369136/2020 Committee for Medicinal Products for Human Use (CHMP).